Key Highlights

  • INVO Fertility (NASDAQ:IVF) was trading down 9.8% at USD 2.42 in pre-market on Friday, November 13, 2026, with no company announcement dated November 11 to November 13 found.
  • A 1-for-4 Reverse Stock Split took effect before the market opened on October 30, 2026; calculated, USD 2.42 equals about USD 0.61 on the old share basis.
  • On November 5, 2026 the company announced a PatientFi Partnership offering patients financing of up to USD 60,000, with an annual rate starting at 3.99% for excellent credit.
  • The company operates four U.S. fertility clinics, and a published headline said second-quarter 2026 Revenue grew 17%.

A Post-Split Slide With No New Headline

INVO Fertility was quoted at USD 2.42 in pre-market, down 9.8%. No company release, filing or analyst action dated November 11 to November 13, 2026 explaining the move was found. The pre-market quote is the figure of record only for this session. The company effected a 1-for-4 reverse stock split before the open on October 30, 2026, so every four old shares became one. Reverse splits raise the quoted price without changing a company's value, and shares often drift lower afterward as holders sell, which fits the slide but is not confirmed as the cause. A pre-market quote on a small stock is thin, and the move should be read with caution.

Reverse-Split Arithmetic and the Listing Angle

Simple arithmetic on the published figures shows the split mechanics: USD 2.42 times one quarter is about USD 0.61, which would have been a sub-USD 1 price on the old basis, a level that can trigger a Nasdaq minimum bid notice. Companies often use reverse splits to regain the USD 1 bid threshold. The reason for this split was not retrieved, so it is treated here as unconfirmed. Small, thinly traded stocks can move sharply on little volume, and quoted moves can reverse once the regular session opens. The reverse split ratio and date come from the company's announcement headline, while the stated reason was not retrieved.

PatientFi Financing, Clinics and Earnings Timing

The company builds, acquires and operates fertility clinics and sells INVOcell, a device for intravaginal culture, an alternative to traditional in-vitro fertilization. It runs four operational clinics. On November 5, 2026 it announced a partnership with PatientFi to give patients monthly payment plans, with financing of up to USD 60,000 subject to Credit approval and a rate that may be higher than the 3.99% advertised. Third-quarter results had not been found as released; last year's came on November 17, 2025, so a mid-November report is possible but unconfirmed. Losses and cash needs remain the main risk. Fertility clinics earn fees per treatment cycle, so patient financing can widen Demand if affordability limits it. Clinic fees and device sales are the two income streams, and a second-quarter release headline highlighted clinic platform profitability.

Where Things Stand

No fresh news explains the drop, and the likeliest context is the aftermath of the reverse split. INVO Fertility (NASDAQ:IVF) was down 9.8% at USD 2.42 in pre-market, about two weeks after a 1-for-4 consolidation, which is a pattern often seen as holders sell into the higher quote. The Business story is a small clinic network adding patient financing, and revenue growth of 17% was cited for the second quarter. Next markers are third-quarter results, cash and any financing. Pre-market quotes can reverse. Investors should weigh the clinic growth story against the lack of any news tied to the drop and the dilution that small-cap financings can bring.